Dr. Lal Path Labs

LALPATHLAB

NSE

BSE

SectorHealthcare Services

Loading chart…

The Quarter story

The two most recent quarterly results, compared side-by-side.

Dr Lal Pathlabs posts strong growth in Q1 FY27, with revenue and profits surging past previous peaks despite rising operational costs.

Revenue grew from ₹670 Cr in Q1 FY26 to ₹798 Cr in Q1 FY27, signaling robust top-line expansion.

Other expenses jumped from ₹124 Cr in Q1 FY26 to ₹150 Cr in Q1 FY27, indicating rising operational overheads.

EBITDA margin expanded from 28.7% in Q1 FY26 to 31.0% in Q1 FY27, showing improved operational efficiency.

Material costs climbed from ₹129 Cr in Q1 FY26 to ₹152 Cr in Q1 FY27, tracking higher test volumes.

Profit after tax rose from ₹134 Cr in Q1 FY26 to ₹170 Cr in Q1 FY27, underscoring strong net earnings.

Collection fees rose from ₹92 Cr in Q1 FY26 to ₹116 Cr in Q1 FY27, reflecting growing network costs.

Patient visits increased from 7.6 Mn in Q1 FY26 to 8.2 Mn in Q1 FY27, confirming steady demand growth.

About the company

Dr Lal PathLabs is a leading diagnostic healthcare service provider in India. The company operates a nationwide network of medical laboratory centers, offering over 5000 diagnostic tests and related healthcare services. Its infrastructure includes a National Reference Laboratory in New Delhi, Regional Reference Labs in Kolkata, Bangalore, and Mumbai, 371 clinical laboratories, 5,102 patient service centers, and 10,938 pickup points as of March 31, 2023. The company provides services to individual patients, hospitals, healthcare providers, and corporate customers. Its test catalog includes 481 test panels, 2763 pathology tests, and 1947 radiology and cardiology tests. Dr Lal PathLabs has expanded through acquisitions and has several domestic and international subsidiaries. The company continues to grow its network and enhance its technological capabilities to improve its diagnostic services.

In the news

Dr Lal PathLabs Q1 profit jumps 27% to ₹170 crore, shares hit 52-week high

Nifty Falls 2.12% in Biggest Drop in 3 Months; Brokerage Picks

Dr Lal Path Labs hits ₹2,234.65 after Kotak double upgrade